FLX Bio, Inc. Email Format
Biotechnology ResearchCalifornia, United States51-200 Employees
FLX Bio, Inc. is a biotechnology company focused on immuno-oncology, developing orally available small molecule drugs intended to activate the immune system against cancer. Its integrated drug discovery platform targets proteins and pathways in the tumor microenvironment, concentrating on regulatory T cells and myeloid cells that influence tumor immunity. The lead candidate, FLX475, is a CCR4 inhibitor that entered Phase 1 in December 2017, with potential use as a monotherapy or in combination with checkpoint inhibitors; the company is also developing inhibitors targeting GCN2 and USP7. Based in South San Francisco, California, FLX Bio operates within the biotechnology research sector and pursues a precision medicine approach by identifying biomarkers to guide prospective patient selection and maximize clinical response. Through its translational biology and computational capabilities, the company aims to advance strategies that modulate the tumor immune microenvironment in cancer therapy.